An ex­pe­ri­enced biotech is stitched to­geth­er from transpa­cif­ic parts, with 265 staffers and a fo­cus on ‘new bi­ol­o­gy’

Over the past few years, dif­fer­ent teams at a pair of US-based biotechs and in labs in Japan have la­bored to piece to­geth­er a group of can­cer drug pro­grams, shar­ing a sin­gle cor­po­rate um­brel­la with re­search col­leagues in Japan. But now their far-flung op­er­a­tions have been knit to­geth­er in­to a sin­gle unit, cre­at­ing a pipeline with 10 can­cer drug de­vel­op­ment pro­grams — go­ing from ear­ly-stage right in­to Phase III — and a host of dis­cov­ery projects man­aged by a col­lec­tive staff of some 265 peo­ple.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA